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STUDY PROTOCOL Open Access
Effects of digital Cognitive Behavioural
Therapy for Insomnia on cognitive function:
study protocol for a randomised controlled
trial
Simon D. Kyle1*, Madeleine E. D. Hurry1,2, Richard Emsley3, Annemarie I. Luik1,4, Ximena Omlin1, Kai Spiegelhalder5,
Colin A. Espie1,4 and Claire E. Sexton2
Abstract
Background: The daytime effects of insomnia pose a significant burden to patients and drive treatment seeking. In
addition to subjective deficits, meta-analytic data show that patients experience reliable objective impairments across
several cognitive domains. While Cognitive Behavioural Therapy for Insomnia (CBT-I) is an effective and scalable
treatment, we know little about its impact upon cognitive function. Trials of CBT-I have typically used proxy
measures for cognitive functioning, such as fatigue or work performance scales, and no study has assessed self-reported
impairment in cognitive function as a primary outcome. Moreover, only a small number of studies have assessed
objective cognitive performance, pre-to-post CBT-I, with mixed results. This study specifically aims to (1) investigate the
impact of CBT-I on cognitive functioning, assessed through both self-reported impairment and objective performance
measures, and (2) examine whether change in sleep mediates this impact.
Methods/design: We propose a randomised controlled trial of 404 community participants meeting criteria for
Insomnia Disorder. In the DISCO trial (Defining the Impact of improved Sleep on COgnitive function (DISCO)) participants
will be randomised to digital automated CBT-I delivered by a web and/or mobile platform (in addition to treatment as
usual (TAU)) or to a wait-list control (in addition to TAU). Online assessments will take place at 0 (baseline), 10 (post-
treatment), and 24 (follow-up) weeks. At week 25, all participants allocated to the wait-list group will be offered
digital CBT-I, at which point the controlled element of the trial will be complete. The primary outcome is self-reported
cognitive impairment at post-treatment (10 weeks). Secondary outcomes include objective cognitive performance,
insomnia severity, sleepiness, fatigue, and self-reported cognitive failures and emotional distress. All main analyses will
be carried out on completion of follow-up assessments and will be based on the intention-to-treat principle.
Further analyses will determine to what extent observed changes in self-reported cognitive impairment and
objective cognitive performance are mediated by changes in sleep. The trial is supported by the National
Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) based at Oxford University Hospitals
NHS Trust and University of Oxford, and by the NIHR Oxford Health BRC.
Discussion: This study will be the first large-scale examination of the impact of digital CBT-I on self-reported
cognitive impairment and objective cognitive performance.
Trial registration: ISRCTN, ID: ISRCTN89237370. Registered on 17 October 2016.
Keywords: Sleep, Insomnia, Cognitive impairment, Cognitive behavioural therapy, Internet
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Background
Insomnia disorder is defined as persistent difficulties
with sleep initiation and/or maintenance, resulting in
significant daytime impairment. Insomnia affects ap-
proximately 10–12% of the adult population and is asso-
ciated with increased risk for cardiovascular disease,
depression, and early mortality [1, 2]. Daytime function-
ing and quality of life are known to be severely affected
in those with insomnia and often drive treatment seek-
ing [3–5]. More specifically, previous work shows that
the most commonly cited areas of daytime dysfunction
are problems with fatigue, work performance, cognitive
functioning, and emotional regulation [6].
With respect to cognitive function, meta-analytic data
indicate that patients exhibit reliable impairments (of
medium effect size) in tasks probing episodic memory,
working memory, and problem solving [7]. Recent, well-
controlled studies also find evidence of insomnia-related
impairments in switching of attention and working
memory [8], and sustained attention and episodic mem-
ory [9]. These impairments are associated with global in-
somnia severity, sleep duration, and disturbed sleep
continuity (from both sleep diaries and polysomnogra-
phy). In general, neurocognitive findings are consistent
with results from functional imaging studies, which re-
veal evidence of hypoactivation within fronto-striatal
networks during task-related functional magnetic reson-
ance imaging (fMRI) [10–13].
Despite cognitive impairment featuring in contempor-
ary diagnostic criteria for insomnia (Diagnostic and Stat-
istical Manual of Mental Disorders, 5th edition: DSM-5;
International Classification of Sleep Disorders, 3rd edi-
tion: ICSD-3) [14], and posing significant burden to pa-
tients, there has been little evaluation of the impact of
insomnia treatments on cognitive function [15]. This is
surprising because cognitive impairment may drive other
daytime impairments associated with insomnia (e.g.
reduced work performance and increased accident risk)
[6, 16]. To date, trials of Cognitive Behavioural Therapy
for Insomnia (CBT-I), the first-line treatment for persist-
ent insomnia disorder [1], have tended to employ proxy
measures (e.g. general daytime functioning, work per-
formance) or nonvalidated, single items to probe self-
reported cognitive functioning as a secondary outcome
[15]. No study has assessed cognitive functioning as a
primary outcome. Moreover, to our knowledge only four
small studies have assessed objective cognitive perform-
ance, pre-to-post CBT-I [10, 17–19], providing prelimin-
ary evidence that sleep improvement may be associated
with improvements in complex attention and executive
function. However, the largest trial to date [19] failed to
observe treatment effects for delayed recall, abstract rea-
soning, or working memory. Thus, it remains unclear if
CBT-I confers reliable improvement to cognitive
performance and to what extent such improvement may
be mediated by reductions in insomnia severity. If insom-
nia causally drives cognitive impairment then we might
logically expect that (1) CBT-I improves both sleep and
cognitive function, and (2) treatment effects on cognition
will operate via the pathway of improved sleep.
The aim of this study, therefore, is to investigate the
impact of CBT-I on cognitive functioning, assessed
through both self-report and objective measures. We
will recruit participants meeting criteria for insomnia
disorder who also endorse cognitive complaints, and
conduct a parallel-group, randomised controlled trial
(RCT) of CBT-I + TAU versus wait-list control (WLC +
TAU). CBT-I will be delivered online via a website and/
or app [20]. Online interventions have shown robust
effects on insomnia severity and self-reported sleep
parameters, with effect sizes in the range of face-to-face
interventions [21, 22]. Assessments, including question-
naires and computerised cognitive tasks, will also be de-
livered and completed fully online. This will be the first
examination of the impact of digital CBT-I (dCBT-I) on
self-reported cognitive impairment and objective per-
formance in participants meeting criteria for insomnia
disorder.
The primary hypothesis for the trial is:
1. dCBT-I will reduce self-reported cognitive impairment
at the end of treatment (10 weeks) relative toWLC
The secondary hypotheses are:
1. dCBT-I will reduce self-reported cognitive impairment
at follow-up (24 weeks) relative toWLC
2. dCBT-I will improve objective cognitive performance
(in the following domains: simple attention, visual
attention, episodic memory, working memory, and
complex processing speed), relative toWLC (10 and
24 weeks)
3. dCBT-I will reduce insomnia severity and improve
sleep efficiency relative to WLC (10 and 24 weeks)
4. Change in insomnia severity and sleep efficiency at
week 10 will mediate change in self-reported
cognitive impairment and objective cognitive
performance at week 24
5. dCBT-I will lead to improvements in fatigue,
sleepiness, self-reported cognitive failures, depression,
and anxiety relative toWLC (weeks 10 and 24)
Methods/design
Research design
The study is a parallel-group, superiority RCT of dCBT-I
(+ TAU) versus WLC (+ TAU). The study will be carried
out completely online. Participants will be administered
screening, informed consent, assessments (tasks and
Kyle et al. Trials  (2017) 18:281 Page 2 of 8
questionnaires), allocation to condition, and intervention
through web-based platforms. Online assessment of our
primary and secondary dependent variables will take
place at 0 (baseline), 10 (post-treatment), and 24 (fol-
low-up) weeks. At week 25 all participants allocated to
the WLC will be offered dCBT-I to improve their insom-
nia (see Fig. 1 for trial design). Ethical approval has been
granted from the University of Oxford Medical Sciences
Inter-Divisional Research Ethics Committee (R46116/
RE001) and the trial is registered at ISRCTN
(ISRCTN89237370).
Participants
We will recruit 404 community participants who report
clinically-significant insomnia. Our inclusion criteria
comprise: (a) a positive screen for probable DSM-5 in-
somnia disorder using items from the Sleep Condition
Indicator (SCI) (scoring ≤2 on item 1 (sleep latency) or
item 2 (wakefulness during the night) + scoring ≤2 on
item 3 (frequency of disturbance) + scoring ≤1 on item 4
(sleep quality) + scoring ≤2 on daytime functioning items
5 or 6 + scoring ≤2 on item 8 (chronicity of problem))
[23], (b) endorsement of difficulties with concentration
or memory using items from the Daytime Functioning
and Sleep Attribution Scale (selecting ‘somewhat of a
problem’ or ‘a very big problem’ on at least one item,
when asked how much of a problem ‘difficulty concen-
trating and focussing on things’ and ‘difficulty remem-
bering things’ has been in the past 2 weeks) [24], (c)
being aged 25 years and above (to minimise the possibil-
ity that circadian rhythm disruption, which is common
in late adolescence/early 20s, is the source of insomnia
complaints), (d) having reliable Internet access at home
or at work, (e) being able to read and understand
English, and (f ) currently living in the UK. We will
screen for comorbid conditions and medication use via
Fig. 1 Flow chart diagram showing summary of the trial design for the Defining the Impact of improved Sleep on COgnitive function (DISCO)
study. DSM-5 Diagnostic and Statistical Manual of Mental Disorders, version 5, SCI Sleep Condition Indicator, dCBT-I digital Cognitive Behavioural
Therapy for Insomnia, WLC Wait-list control
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online survey and exclude people with (1) symptoms of
a probable additional sleep disorder (e.g. possible ob-
structive sleep apnoea, restless legs syndrome [25]), (2)
diagnosis of mild cognitive impairment or dementia, (3)
psychosis or mania, (4) serious physical health concerns
necessitating surgery or with a prognosis of under
6 months, (4) those undergoing a psychological treat-
ment programme for insomnia with a health profes-
sional, (5) habitual night shift, evening, or rotating shift-
workers, (6) those taking prescribed sleeping pills more
than 2 nights in the past 2 weeks prior to study entry,
and (7) those with suicidal ideation with intent. We will
not omit participants for any other physical or mental
health problems. The study will recruit through multiple
channels. These include online, print and broadcast
media advertisements, and the use of contact lists where
adults who have agreed to be contacted about future
studies will be notified about the DISCO trial. In
addition to receiving free access to the dCBT-I
programme, participants will also receive payment in the
form of Amazon™ gift vouchers for completing each as-
sessment point (£5 for baseline; £10 for post-treatment;
£15 for follow-up).
Randomisation and allocation concealment
This study will use simple randomisation with an alloca-
tion ratio of 1:1, as recommended for large clinical trials
[26]. Randomisation will be carried out using the ran-
domisation function within Qualtrics Survey Software
(Qualtrics, Provo, UT, USA). On completion of baseline
measures, each subject will be randomly assigned by the
software to either dCBT-I or WLC. The research team,
therefore, will be unable to influence randomisation and
will have no access to future allocations.
Blinding
Self-report assessments and performance tasks will be
completed entirely online. Participants will be informed of
their randomisation outcome (dCBT-I or WLC) via email,
and so they will not be blind to treatment allocation. The
research team, except the trial coordinator, will be blind to
allocation. The trial coordinator will not be blind since
they will inform participants of group allocation and moni-
tor completion of assessments. Participant contact with
the trial coordinator will be limited to scripted phrases, de-
tailing instructions for dCBT-I access and completion of
assessments, and will not cover therapy content or sup-
port. Statistical analyses will be conducted by a member of
the research team who will have access to all data.
Assessment points
Assessments will take place at weeks 0 (baseline), 10
(post-treatment), and 24 (follow-up) (see Fig. 2). Partici-
pants are advised to allow enough time to complete the
questionnaires and cognitive tasks in one session, on
their home computer or laptop in a quiet, distraction-
free environment. On completion of the trial (week 25),
all participants in the control arm will be offered access
to dCBT-I. Baseline variables include demographic infor-
mation such as age, gender, ethnic group, partner status,
employment status, and education. Frequency of sleep
medication use will also be monitored at each assess-
ment point.
Intervention
dCBT-I will be delivered using the Sleepio® programme
(www.sleepio.com and associated Sleepio® app) [19]. We
have previously described the Sleepio® programme in
two trial protocols published in this journal [27, 28]. The
programme is fully automated and its underlying algo-
rithms drive the delivery of information, support, and
advice in a personally tailored manner. Delivery is struc-
tured into six weekly sessions, lasting an approximately
20 min each. The full programme can be accessed via
the website or iOS app. Treatment content is based on
CBT-I manuals and includes a behavioural component
(sleep restriction, stimulus control, and relaxation), a
cognitive component (paradoxical intention, cognitive
restructuring, mindfulness, positive imagery, and putting
the day to rest) and an educational component (psychoe-
ducation and sleep hygiene) [29–31].
The programme is highly interactive, and content is
presented by an animated virtual therapist (‘The Prof ’).
Before the start of the programme, participants complete
a questionnaire to tailor the therapy and to set treatment
goals. Participants complete daily sleep diary information
throughout the intervention, which is used by the
programme to provide tailored, personalised advice. Par-
ticipants can opt to receive an email and/or SMS re-
minder each morning to prompt them to fill in their
sleep diary. In addition, throughout the course of ther-
apy, participants have access to an online community
forum; weekly sleep expert sessions moderated by a clin-
ical psychologist; and online library of information about
sleep and sleep disorders. During weekly sleep expert
sessions, users may vote on topics and submit questions
to be addressed by the clinical psychologist. Questions
are answered in such a way as to benefit as many people
as possible and no personal medical advice is provided.
Participants can view their online ‘case file’, which in-
cludes four sections: a progress review, a 'to-do' list, an
agreed sleep schedule, and a list of further reading. The
system provides online analytics which can be used to
monitor adherence by assessing how many sessions were
completed and the number of weeks to complete the
course. All information gathered during the programme
will be stored in encrypted form on secure servers. Par-
ticipants will have access to the intervention for up to
Kyle et al. Trials  (2017) 18:281 Page 4 of 8
12 weeks. dCBT-I will in effect be dCBT-I + TAU be-
cause there will be no requirement for participants (in
either group) to alter their usual care in any way.
Outcome measures
Our primary outcome will be self-reported cognitive im-
pairment, assessed using the British Columbia Cognitive
Complaints Inventory (BC-CCI) [32]. The BC-CCI com-
prises six questions scored using a 4-point scale (0–3
points; total score range: 0–18) probing perceived cogni-
tive problems (with concentration, memory, and think-
ing skills) during the past 7 days. It was originally
designed to probe cognitive complaints in those with
depression – a disorder highly comorbid with insomnia,
and sharing similar cognitive features [33]. Given the ab-
sence of a widely used measure of insomnia-related cog-
nitive impairment the BC-CCI was selected based on
good face validity, internal consistency data (Cronbach’s
alpha = 0.82–0.86), and short (1-week) reference period.
Secondary measures
Objective cognitive performance will be assessed through
an online battery of tasks and will include measures of
simple attention (dependent variable [DV]: simple reac-
tion time [msec] for correct identification of matching
pairs [‘snap’]), episodic memory (DV: number of at-
tempts to identify identical pairs of cards within a
matrix), working memory (DV: longest sequence of cor-
rectly recalled digits), visual attention (DV: time taken
[secs] to link numbered circles), and complex processing
speed (DV: number of correctly matched digit-symbols
within a 2-min interval). The battery was developed by
the UK Biobank Cognitive Psychology Sub-Group for
Cognitive Assessments. Prior to task commencement,
participants are asked which text entry and pointing
methods they will use to complete tasks (e.g. on full-
sized keyboard, touchscreen, laptop trackpad or mouse).
Insomnia severity
Participants will complete the Insomnia Severity Index
(ISI) [34] to quantify global insomnia severity. The ISI is
a seven-item insomnia assessment tool, probing both
nighttime and daytime aspects of insomnia disorder, and
is sensitive to change following CBT-I. It is a recom-
mended outcome measure in insomnia trials [35]. The
ISI will be supplemented with four items from the
Activity/Assessment t-1 t0 t1 t2
Pre-study Baseline 
(Week 0)
Post-
treatment 
(Week 10)
Follow-up 
(Week 24)
Eligibility screen X
Informed consent X
Baseline assessment X
Randomisation X
Interventions: dCBT-I and Wait-list control X (6 
dCBT-I 
sessions 
completed 
over a 
minimum 
of 6 
weeks)
Demographics X
Chronotype (one item from MEQ) X
Self-reported cognitive impairment (BC-
CCI )
X X X
Objective cognitive performance (Biobank 
task battery)
X X X
Quantitative sleep parameters (four items 
from PSQI)
X X X
Insomnia Severity (ISI) X X X
Fatigue (MFI) X X X
Sleepiness (ESS) X X X
Cognitive failures (CFQ) X X X
Depression (PHQ-9) X X X
Anxiety (two items from GAD-7) X X X
Self-reported adverse-effects checklist X
Audit of engagement with sleep therapies X X
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure
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Pittsburgh Sleep Quality Index (PSQI) [36] to permit
calculation of quantitative sleep parameters, namely:
total time in bed, sleep-onset latency, total sleep time,
and sleep efficiency.
Fatigue
Fatigue will be assessed with the Multidimensional Fa-
tigue Inventory (MFI) [37], a 20-item measure compris-
ing five subscales; general fatigue, physical fatigue,
mental fatigue, reduced motivation and reduced activity.
Sleepiness
Daytime somnolence will be assessed with the Epworth
Sleepiness Scale (ESS) [38], an eight-item measure (score
range: 0–24) probing propensity for ‘dosing’ in a range
of daytime situations.
Cognitive failures
Self-reported cognitive failures will be assessed with the
Cognitive Failures Questionnaire (CFQ) [39]. The CFQ
comprises 25 questions scored using a 5-point Likert
scale (range: 0–100) to identify frequency of minor cog-
nitive mistakes over the past month.
Depression
Depressive symptoms will be measured using the nine-
item (score range: 0–27) Patient Health Questionnaire
(PHQ-9) [40].
Anxiety
Symptoms of anxiety will be assessed using two items
[‘Feeling nervous, anxious, or on edge’, ‘not being able to
stop or control worrying’; score range: 0–6] from the
seven-item Generalised Anxiety Disorder 7 question-
naire (GAD-7) [41].
Assessment of safety
The likelihood of serious adverse events occurring dur-
ing this trial is low since CBT-I (in any format) has not
been reported to cause them. The intervention offered
in the trial has previously been tested in a randomised,
placebo-controlled trial and no adverse outcomes were
reported [20]. Since the trial is completed fully online,
without formal participant contact, we are unlikely to
become aware of potential adverse events. However,
should we do so, we will define serious adverse events
as: (1) death, (2) suicide attempt, (3) admission to hos-
pital, and (4) formal complaints about the online
intervention.
Studies have shown that daytime sleepiness and vigi-
lance impairment may increase during Sleep Restriction
Therapy (SRT) (one component of CBT-I), owing to re-
stricted sleep opportunity. At the end of treatment (week
10), we will, therefore, ask participants to complete an
adapted version of a previously used measure to assess
differential rates of self-reported adverse effects [42].
Sample size calculation
Our planned primary intention-to-treat analysis will
compare dCBT-I + TAU versus WLC + TAU for self-
reported cognitive impairment (BC-CCI). A systematic
review of the cognitive functioning and CBT-I literature
shows a standardised mean difference of 0.42 at post-
treatment for self-reported outcomes [15]. We will re-
cruit and randomise 404 participants (202 participants/
arm). This sample size will give 90% power to detect a
minimum standardised effect size of 0.42 at 5% level of
significance, accounting for 40% attrition.
Statistical analysis
In accordance with Consolidated Standards of Reporting
Trials (CONSORT) guidelines, we will record and report
all participant flow [43]. Descriptive statistics of recruit-
ment, dropout, and completeness of interventions will
be provided. The main efficacy analysis will be via
intention-to-treat including all participants, with no
planned interim analysis for efficacy or futility. Baseline
characteristics will be presented by randomised group
without formal statistical tests. We will test the primary
hypothesis for between-group change in the primary
outcome (BC-CCI) at 10 weeks using analysis of covari-
ance with baseline outcome measure and treatment as-
signment as fixed effects, and apply standard regression
diagnostics. The analysis will use statistical techniques
for handling missing outcome data under a missing-at-
random assumption. Secondary outcomes will be ana-
lysed using an analogous method. Analysis of all treat-
ment effects will be undertaken after follow-up (week
24) assessments are completed. Additional exploratory
analyses will assess whether age moderates treatment-
related effects on cognitive functioning outcomes.
We will use modern causal inference methods to investi-
gate the mediation hypothesis. If the efficacy analysis
shows significant between-group differences in the ISI and
sleep efficiency (based on PSQI items) at 10 weeks, then
we will use parametric regression models to test for the in-
direct effect of ISI/sleep efficiency on primary and second-
ary cognitive outcomes at 24 weeks, and the residual
direct effect of treatment on cognitive outcomes at
24 weeks. Since all the measures are continuous, the indir-
ect effects are calculated by multiplying relevant pathways
and bootstrapping is used to produce valid standard errors
for the indirect effects. All analyses will adjust for baseline
measures of the mediators (ISI/sleep efficiency), outcomes
and putative measured confounders. Mediation analyses
are potentially biased by measurement error in mediators
and hidden confounding between mediators and outcomes
and we will investigate the sensitivity of the estimates
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to these problems. All analyses will be carried out
using Stata [44].
Dissemination
We will publish the results of this study in peer-
reviewed journals, irrespective of magnitude or direction
of effect. Findings will also be presented at both national
and international scientific meetings. The results will be
made available online wherever possible, if permitted by
journal policies.
Items in this protocol comply with the Standard
Protocol Items: Recommendations for Interventional Tri-
als (SPIRIT) Checklist (see SPIRIT Checklist in Additional
file 1 and Fig. 2 for the SPIRIT figure).
Discussion
Insomnia is a prevalent, persistent and impairing sleep
disorder. Patients consider cognitive dysfunction as one
of the most important consequences of insomnia, yet we
do not know whether such dysfunction can be amelio-
rated through evidence-based intervention. This study
will determine whether treating insomnia with dCBT-I
improves both self-reported cognitive impairment and
objective cognitive performance, and whether change in
insomnia severity and sleep efficiency mediates such
improvement.
Trial status
Recruitment commenced on 18 October 2016 and is
ongoing.
Additional file
Additional file 1: SPIRIT Checklist. (DOCX 51 kb)
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